Quotient (NASDAQ: QTNT) and Oxford Immunotec Global (NASDAQ:OXFD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk and institutional ownership.
Risk and Volatility
Quotient has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500. Comparatively, Oxford Immunotec Global has a beta of -0.27, indicating that its share price is 127% less volatile than the S&P 500.
This table compares Quotient and Oxford Immunotec Global’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Quotient||$24.73 million||14.27||-$82.33 million||($2.02)||-3.83|
|Oxford Immunotec Global||$103.08 million||3.22||-$32.88 million||($1.36)||-9.43|
Oxford Immunotec Global has higher revenue and earnings than Quotient. Oxford Immunotec Global is trading at a lower price-to-earnings ratio than Quotient, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent recommendations for Quotient and Oxford Immunotec Global, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Oxford Immunotec Global||0||0||4||0||3.00|
Quotient presently has a consensus target price of $11.50, suggesting a potential upside of 48.77%. Oxford Immunotec Global has a consensus target price of $18.25, suggesting a potential upside of 42.36%. Given Quotient’s higher probable upside, equities research analysts plainly believe Quotient is more favorable than Oxford Immunotec Global.
This table compares Quotient and Oxford Immunotec Global’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Oxford Immunotec Global||-34.13%||-43.51%||-24.49%|
Institutional & Insider Ownership
61.5% of Quotient shares are owned by institutional investors. Comparatively, 91.8% of Oxford Immunotec Global shares are owned by institutional investors. 29.0% of Quotient shares are owned by insiders. Comparatively, 6.6% of Oxford Immunotec Global shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Oxford Immunotec Global beats Quotient on 7 of the 13 factors compared between the two stocks.
Quotient Company Profile
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood-group antigens; reagent red blood cells, which enable the identification of blood-group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.
Oxford Immunotec Global Company Profile
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology. The company develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. It develops and markets T-SPOT.TB test used to test for tuberculosis. The company is also developing a range of assays for tick-borne diseases, such as lyme disease, as well as for use in screening blood for the parasite babesia microti that causes babesiosis; and T-SPOT.CMV test that measures the strength of a patient's cellular response to CMV infection. Oxford Immunotec Global PLC markets its T-SPOT.TB test through a direct sales force in the United States, certain European countries, and Japan, as well as through distributors in other parts of the world. Oxford Immunotec Global PLC was founded in 2002 and is headquartered in Abingdon, the United Kingdom.
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.